skip to Main Content

Dr. O’Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

Dr. O’Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer
Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.

Watch here . . .


Back To Top